 |
41 Diseases |  |
1 Trial |
|
1 Trial |  |
103 News |  |
| 12» |
- || davamotecan pegadexamer (EP0057) / Ellipses Pharma
Clinical, Clinical data, Retrospective data, Review: Clinical Outcomes and Effectiveness of CRLX101 for Solid Tumors: A Systematic Review and Meta-analysis. (Pubmed Central) - Feb 28, 2024
Unresolved pharmacology limits carrier-mediated drug therapeutic application. Carrier-mediated dosages may differ from normal formulations because they are rarely studied.
- ||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion, Enrollment change, Combination therapy, Metastases: EP0057 in Combination With Olaparib in Advanced Ovarian Cancer (clinicaltrials.gov) - Aug 2, 2023
P2, N=34, Completed, Sponsor: Ellipses Pharma
Carrier-mediated dosages may differ from normal formulations because they are rarely studied. Active, not recruiting --> Completed | N=60 --> 34
- || davamotecan pegadexamer (EP0057) / Ellipses Pharma
Review, Journal: A Systematic Review of Clinical Trials on the Efficacy and Safety of CRLX101 Cyclodextrin-Based Nanomedicine for Cancer Treatment. (Pubmed Central) - Jul 29, 2023
CRLX101 was often combined with other therapeutic agents, resulting in improvements such as increased progression-free survival and clinical benefit rates. Toxicity was generally manageable, with common adverse events including fatigue, nausea, and anemia.
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment change, Trial withdrawal, Combination therapy, Metastases: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer (clinicaltrials.gov) - Jun 12, 2023
P2, N=0, Withdrawn, Sponsor: Ellipses Pharma
Toxicity was generally manageable, with common adverse events including fatigue, nausea, and anemia. N=115 --> 0 | Not yet recruiting --> Withdrawn
- || davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial initiation date, Combination therapy, Metastases: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer (clinicaltrials.gov) - Nov 2, 2022
P2, N=115, Not yet recruiting, Sponsor: Ellipses Pharma
N=115 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Jul 2022 --> Apr 2023
- || davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment closed, Trial completion date, Combination therapy, Metastases: EP0057 in Combination With Olaparib in Advanced Ovarian Cancer (clinicaltrials.gov) - Nov 2, 2022
P2, N=60, Active, not recruiting, Sponsor: Ellipses Pharma
Initiation date: Jul 2022 --> Apr 2023 Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Mar 2023
- || EP0057 / Ellipses Pharma
P2 data, Journal: A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. (Pubmed Central) - Sep 10, 2022
P2
Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Mar 2023 NLG207 12 mg/m2 in combination with enzalutamide was not well tolerated in patients with mCRPC following several lines of the standard of care therapy.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial termination, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Jul 12, 2022
P2, N=4, Terminated, Sponsor: National Cancer Institute (NCI)
NLG207 12 mg/m2 in combination with enzalutamide was not well tolerated in patients with mCRPC following several lines of the standard of care therapy. Completed --> Terminated; Study was closed for toxicity.
- |||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
New P2 trial, Combination therapy, Metastases: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer (clinicaltrials.gov) - Jun 8, 2022
P2, N=115, Not yet recruiting, Sponsor: Ellipses Pharma
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion date, Trial primary completion date, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Feb 8, 2022
P2, N=3, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Study was closed for toxicity. Trial completion date: Feb 2022 --> Jun 2021 | Trial primary completion date: Feb 2022 --> May 2021
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion, Trial completion date, Trial primary completion date, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Feb 4, 2022
P2, N=3, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Feb 2022 --> Jun 2021 | Trial primary completion date: Feb 2022 --> May 2021 Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2022 | Trial primary completion date: Dec 2022 --> Feb 2022
- || NLG207 / Ellipses Pharma, Avastin (bevacizumab) / Roche
Clinical, P2 data, Journal, Combination therapy, Monotherapy: Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. (Pubmed Central) - Jan 7, 2022
Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2022 | Trial primary completion date: Dec 2022 --> Feb 2022 CRLX101 meets the clinical need for an effective and tolerable topoisomerase I inhibitor and can be safely combined with bevacizumab.
- | Xtandi (enzalutamide) / Pfizer, Astellas, Bausch Health, NLG207 / Ellipses Pharma
Preclinical, Journal, Combination therapy: Anti-tumor activity of NLG207 (formerly CRLX101) in combination with enzalutamide in preclinical prostate cancer models. (Pubmed Central) - Dec 30, 2021
P2
Combination treatment with NLG207 and enzalutamide was shown to be effective in preclinical prostate cancer models of enzalutamide resistance. Clinical investigation of this treatment combination is ongoing (NCT03531827).
- || NLG207 / Ellipses Pharma, Avastin (bevacizumab) / Roche
Clinical, P1/2 data, PK/PD data, Journal, Combination therapy: A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Pubmed Central) - Aug 6, 2021
P1/2
EP0057 exhibits high plasma drug retention, slow clearance, and controlled slow release of CPT from the polymer when administered alone and with paclitaxel. (NCT02389985) 242 words.
- || davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial primary completion date, Combination therapy, Metastases: EP0057 in Combination With Olaparib in Advanced Ovarian Cancer (clinicaltrials.gov) - Jul 6, 2021
P2, N=60, Recruiting, Sponsor: Ellipses Pharma
(NCT02389985) 242 words. Trial primary completion date: Jul 2022 --> Nov 2022
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment closed, Enrollment change, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Jun 30, 2021
P2, N=3, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2022 --> Nov 2022 Recruiting --> Active, not recruiting | N=30 --> 3
- || NLG207 / Ellipses Pharma
Clinical, PK/PD data, Journal: Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. (Pubmed Central) - May 21, 2021
P1/2, P2
The popPK model confirmed nanoparticle behavior of conjugated CPT and mechanistically characterized CPT release from NLG207. The current analysis provides a strong foundation for future study as a potential predictive tool in ongoing NLG207 clinical trials.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion date, Trial primary completion date, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Apr 22, 2021
P2, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
The current analysis provides a strong foundation for future study as a potential predictive tool in ongoing NLG207 clinical trials. Trial completion date: Dec 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Dec 2022
- ||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment open, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: EP0057 in Combination With Olaparib in Advanced Ovarian Cancer (clinicaltrials.gov) - Dec 16, 2020
P2, N=60, Recruiting, Sponsor: Ellipses Pharma
Trial completion date: Dec 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Dec 2022 Not yet recruiting --> Recruiting
- |||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
New P2 trial, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: EP0057 in Combination With Olaparib in Advanced Ovarian Cancer (clinicaltrials.gov) - Dec 16, 2020
P2, N=60, Not yet recruiting, Sponsor: Ellipses Pharma
- | NLG207 / Ellipses Pharma
Journal: Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma. (Pubmed Central) - Dec 1, 2020
P1/2, P2
NLG207 NDCs demonstrated significant rates of CPT release in human plasma at room temperature after 2 h but were shown to be stable at 4 °C for 24 h and through 4 freeze/thaw cycles. This assay was used to quantitate CPT plasma concentrations in clinical samples to confirm clinical utility following NLG207 treatment in subjects with advanced prostate cancer.
- ||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial termination, Metastases: Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer (clinicaltrials.gov) - Nov 3, 2020
P1/2, N=32, Terminated, Sponsor: UNC Lineberger Comprehensive Cancer Center
This assay was used to quantitate CPT plasma concentrations in clinical samples to confirm clinical utility following NLG207 treatment in subjects with advanced prostate cancer. Active, not recruiting --> Terminated; The study was halted prematurely at the funding partner's request.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion date, Trial primary completion date, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Apr 15, 2020
P2, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; The study was halted prematurely at the funding partner's request. Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- | irinotecan / Generic mfg.
Review, Journal: Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers. (Pubmed Central) - Feb 25, 2020
Conjugated with cyclodextrin-based polymers not only reduce adverse effects but also modulate the immune responses to elevate drug efficacy. These immune responses may potentially facilitate actions of immune blockage, such as PD1/PDL1 in cancer treatment.
- ||||| Xtandi (enzalutamide) / Pfizer, Astellas, NLG207 / Ellipses
Clinical: Nice work by Dr. Kieth Schmidt of Figg Lab @theNCI @WilliamFigg1 @Cody_J_Peer https://t.co/e1Lv1tf5uj Rationale supporting #ProstateCancer #ClinicalTrial @theNCI with #enzalutamide+NLG207(in pts already treated with enzalutamide) trial: https://t.co/kIH22EtSpJ (Twitter) - Jan 22, 2020
- || NLG207 / Ellipses Pharma, capecitabine / Generic mfg.
Clinical, P1/2 data, Journal: Phase I/II trial of Nano-camptothecin CRLX101 with Capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal Cancer. (Pubmed Central) - Dec 6, 2019
P1/2
CRLX101 at 15mg/m weekly with neoadjuvant CRT is a feasible combination strategy with an excellent toxicity profile. Clinicaltrials.govregistrationNCT02010567.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion date, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Apr 18, 2019
P2, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Clinicaltrials.govregistrationNCT02010567. Trial completion date: Jun 2020 --> Jun 2021
- | CRLX 101 / NewLink Genetics
Journal: Establishment of a Tm-shift Method for Detection of Cat-Derived Hookworms. (Pubmed Central) - Apr 13, 2019
...To establish a Tm-shift method for the detection of Ancylostoma ceylanicum and A. tubaeforme in cats, specific primers, with GC tail of unequal length attached to their 5 Ì end, were designed based on 2 SNP loci (ITS101 and ITS296) of the internal transcribed spacer 1 (ITS1) sequences...In the clinical detection of hookworm in 69 stray cat fecal sample, the Tm-shift detection results were consistent with the microscopic examination and successfully differentiated between the 2-hookworm species. In conclusion, the developed method is a rapid, sensitive and accurate technique and can provide a promising tool for clinical detection and epidemiological investigation of cat-derived hookworms.
- ||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion date, Trial termination, Trial primary completion date, Combination therapy: A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Feb 25, 2019
P1/2, N=30, Terminated, Sponsor: NewLink Genetics Corporation
In conclusion, the developed method is a rapid, sensitive and accurate technique and can provide a promising tool for clinical detection and epidemiological investigation of cat-derived hookworms. Trial completion date: Aug 2017 --> Oct 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Jun 2018; Company decision
- davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment change, Trial completion date, Trial termination, Combination therapy, Metastases: Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors (clinicaltrials.gov) - Feb 25, 2019
P1, N=41, Terminated, Sponsor: NewLink Genetics Corporation
Trial completion date: Aug 2017 --> Oct 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Jun 2018; Company decision N=61 --> 41 | Trial completion date: Dec 2017 --> May 2018 | Active, not recruiting --> Terminated; Company decision
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion date, Trial primary completion date, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Dec 13, 2018
P2, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
N=61 --> 41 | Trial completion date: Dec 2017 --> May 2018 | Active, not recruiting --> Terminated; Company decision Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment open, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Oct 17, 2018
P2, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020 Not yet recruiting --> Recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion date, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - Sep 11, 2018
P2, N=30, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Jun 2020 --> Mar 2020
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Combination therapy, Metastases: CRLX101 Plus Bevacizumab in Advanced RCC (clinicaltrials.gov) - Aug 29, 2018
P1b, N=22, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial completion date: Jun 2020 --> Mar 2020 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Jul 2017
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Jul 2, 2018
P2, N=63, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Jul 2017 Active, not recruiting --> Completed
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, davamotecan pegadexamer (EP0057) / Ellipses Pharma
New P2 trial, Metastases: Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment (clinicaltrials.gov) - May 27, 2018
P2, N=30, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion date, Metastases: Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer (clinicaltrials.gov) - Apr 25, 2018
P1/2, N=32, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Trial completion date: Dec 2022 --> Sep 2021
- | NLG207 / Ellipses Pharma, Avastin (bevacizumab) / Roche
Clinical, P2 data, Journal, Combination therapy: A randomized phase 2 trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. (Pubmed Central) - Mar 4, 2018
P2
Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2)...Further development in this disease is not planned. NCT02187302 (NIH).
- | NLG207 / Ellipses Pharma, Avastin (bevacizumab) / Roche
Clinical, New P1 trial, P1/2 data, Journal, Combination therapy: Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. (Pubmed Central) - Dec 27, 2017
This combination fulfilled the protocol's predefined threshold for further examination with responses and prolonged PFS in a heavily pretreated population. A randomized phase II clinical trial in mRCC of this combination is ongoing.
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma
Phase classification, Surgery, Metastases: Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery (clinicaltrials.gov) - Nov 8, 2017
P2, N=10, Completed, Sponsor: City of Hope Medical Center
A randomized phase II clinical trial in mRCC of this combination is ongoing. Phase classification: P=N/A --> P2
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Oct 2, 2017
P2, N=63, Active, not recruiting, Sponsor: Massachusetts General Hospital
Phase classification: P=N/A --> P2 Trial primary completion date: Mar 2017 --> Mar 2018
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma
Phase classification, Metastases: Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - Apr 20, 2017
P1b/2a, N=62, Completed, Sponsor: NewLink Genetics Corporation
Trial primary completion date: Mar 2017 --> Mar 2018 Phase classification: P1/2 --> P1b/2a
- || davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors (clinicaltrials.gov) - Apr 20, 2017
P1, N=61, Active, not recruiting, Sponsor: NewLink Genetics Corporation
Phase classification: P1/2 --> P1b/2a Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Oct 2017
- |||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial completion, Trial primary completion date, Combination therapy, Metastases: CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) (clinicaltrials.gov) - Apr 20, 2017
P2, N=115, Completed, Sponsor: NewLink Genetics Corporation
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Oct 2017 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016
- davamotecan pegadexamer (EP0057) / Ellipses Pharma
Trial withdrawal: Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. (clinicaltrials.gov) - Apr 13, 2017
P2, N=0, Withdrawn, Sponsor: Cerulean Pharma Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016 Terminated --> Withdrawn
- ||| davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment closed, Trial primary completion date, Metastases: Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer (clinicaltrials.gov) - Mar 21, 2017
P1/2, N=71, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Terminated --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Oct 2016
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Enrollment change, Trial primary completion date, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Feb 16, 2017
P2, N=63, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Oct 2016 N=29 --> 63 | Trial primary completion date: Apr 2016 --> Mar 2017
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment closed, Combination therapy: A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 31, 2017
P1/2, N=40, Active, not recruiting, Sponsor: Cerulean Pharma Inc.
N=29 --> 63 | Trial primary completion date: Apr 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- || davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors (clinicaltrials.gov) - Sep 2, 2016
P1, N=61, Recruiting, Sponsor: Cerulean Pharma Inc.
Recruiting --> Active, not recruiting N=36 --> 61 | Trial primary completion date: Apr 2016 --> Dec 2016
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment open, Phase classification, Enrollment change, Combination therapy: A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Jul 20, 2016
P1/2, N=40, Recruiting, Sponsor: Cerulean Pharma Inc.
N=36 --> 61 | Trial primary completion date: Apr 2016 --> Dec 2016 Active, not recruiting --> Recruiting | Phase classification: P1 --> P1/2 | N=18 --> 40